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Abstract
Type 2 diabetes (T2D) shares some common risk factors with psoriasis. We evaluated the
association between psoriasis and risk of incident T2D among women and men in the United
States in a mixed retrospective-prospective cohort study. 184,395 participants were included from
an older cohort of women (the Nurses’ Health Study, NHS) (1996–2008), a younger cohort of
women (NHS II) (1991–2007) and an older cohort of men (Health Professionals’ Follow-Up
Study, HPFS) (1986–2006). During 2,700,958 person-years of follow-up, 9,938 incident T2D
cases were confirmed. We found a significantly increased risk of T2D associated with psoriasis
only among younger women (NHS II); multivariate-adjusted relative risk (RR) (95% confidence
interval (CI)) was 1.25 1.05–1.49). When only including those younger than 60 years during
follow-up (NHS and HPFS), we observed a non-significant trend toward increased risk for T2D.
In a pooled-analysis of the three cohorts, psoriatics younger than 60 years were at a higher risk of
T2D; RR 1.26 (1.08–1.48) for women, and 1.26 (1.08–1.46) for both sexes combined. Further, the
risk of T2D was much higher for those developing psoriasis at an early age. In conclusion, we
found an association between psoriasis and risk of T2D among individuals younger than 60 years.
Keywords
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INTRODUCTION
Psoriasis is a common immune-mediated disease of the skin characterized by inflammatory
and hyperproliferative changes (Lowes et al., 2007). Now considered a systemic disorder,
psoriasis affects populations all over the world, with an estimated prevalence of 2.2% to
2.6% In the United States (US) (Gelfand et al., 2005). Although the etiology remains to be
elucidated further, present evidence suggests that psoriasis pathophysiology involves the
interaction of genetic predisposition, immune response, and environmental risk factors such
as smoking, alcohol intake and obesity (Gudjonsson et al., 2004; Loffredo et al., 2009;
Qureshi et al., 2010; Setty et al., 2007a, b).
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tDiabetes has been a major public health concern in the US, with a prevalence of 8.3% in
2010 (http://www.cdc.gov/diabetes/pubs/estimates11.htm#1, accessed 22 June, 2011). The
prevalence of co-morbidities such as insulin resistance, metabolic syndrome and type 2
diabetes (T2D) associated with psoriasis has gained interest in recent years, while most were
cross-sectional (Cohen et al., 2008; Driessen et al., 2009; Henseler and Christophers, 1995;
Kimball et al., 2008; Lindegard, 1986; Love et al., 2011; Neimann et al., 2006; Pearce et al.,
2005) or case-control studies (Brauchli et al., 2008; Gerdes et al., 2008; Gisondi et al., 2007;
Naldi et al., 2008; Shapiro et al., 2007; Sommer et al., 2006; Vena et al., 2010; Wu et al.,
2008), and inflammation seems to be an underlying mechanism (Davidovici et al., 2010; Hu
et al., 2004; Pradhan et al., 2001).
There has been three cohort studies on this topic while two of them did not adjust for the
major risk factors of T2D (Kaye et al., 2008; Solomon et al., 2010). Another cohort study
was a preliminary report from our group (Qureshi et al., 2009). In that analysis, diabetes or
hypertension was evaluated as independent outcomes and it only utilized participants from
NHS II. We had not obtained the complete data for women with psoriasis and no confirmed
cases of psoriasis and T2D were used at that time. Although that study obtained a significant
association, covariates were not fully adjusted for. Therefore, further evidence from large
cohort studies is warranted to evaluate the association. In our study we investigated the
association between psoriasis and T2D in a total population of 184,395 participants from the
Nurses’ Health Study (NHS), NHS II and Health Professionals’ Follow-Up Study (HPFS). It
has been recognized that psoriasis occurs in a bimodal age distribution and type 1 psoriasis
is generally early onset, severe and hereditary (females, 16 years; males, 22 years), while
type 2 psoriasis is late onset (females, 60 years; males, 57 years) (Henseler and
Christophers, 1985; Langley et al., 2005). Therefore, we performed analysis for those
younger than 60 years during the follow-up and evaluated age as a potential effect modifier
of the association between psoriasis and risk of incident T2D. In addition to analyses in
individual cohorts, combined analyses from different cohorts were performed to explore the
association further.
Results
A total of 184,395 participants were included, including 63,927 females from NHS, 95,779
females from NHS II and 24,689 males from HPFS. Characteristics of the participants
according to the diagnosis of psoriasis at the beginning of follow-up are listed in table 1. The
mean age was sharply different among three cohorts. In addition, women and men with
psoriasis were more likely to be smokers and have higher body mass index (BMI).
After 735,664, 1,496,867 and 468,427 person-years of follow-up, we documented 4,280,
3,968 and 1,690 incident T2D for NHS, NHS II and HPFS respectively. For NHS II,
psoriasis was associated with elevated risk of T2D, age-adjusted and multivariate-adjusted
relative risks (RRs) were 1.76 [95% confidence interval (CI): 1.48–2.09] and 1.25 (95% CI:
1.05–1.49) respectively. BMI is a known major risk factor mediating the risk of diabetes and
psoriasis independently. We found differences in the association between psoriasis and
diabetes when only adjusting for age and BMI (RR = 1.33, 95% CI: 1.12–1.58) versus not
adjusting for BMI but other covariates (RR = 1.50, 95% CI: 1.26–1.78). For NHS and
HPFS, no significant association was found in multivariable analysis (table 2).
We performed further analyses by including only those younger than 60 years during the
follow-up (table 3). For NHS and HPFS, 28,834 and 20,708 participants were included
respectively. All the NHS II participants were younger than 60 years prior to the return date
of 2005 questionnaire. Although analyses did not reach statistical significance in
multivariate models, increased RRs were observed among those younger than 60 years old
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tin the NHS (RR = 1.35, 95% CI: 0.89–2.05) and HPFS (RR = 1.20, 95% CI: 0.79–1.82),
which are very similar to what we observed in NHS II. Pooled results of NHS and NHS II
indicated for women younger than 60 years, psoriasis was associated with 26% increased
risk of T2D (RR, 1.26, 95% CI: 1.06–1.48). Pooled results of three cohorts indicated for all
participants younger than 60 years during the follow-up, psoriasis was associated with 26%
increased risk of T2D (RR, 1.26, 95% CI: 1.08–1.46). No heterogeneity was observed
among these cohorts (P = 0.919 and 0.731 for NHS/NHS II/HPFS and NHS/NHS2
respectively).
We analyzed the association of age of psoriasis diagnosis with the risk of incident T2D for
NHS II. We obtained significant results only for cases diagnosed at <40 years (RR = 1.81,
95% CI: 1.14–2.89), rather than those diagnosed at 40–49 or ≥50 years (table 4).
We evaluated the effect modification of menopausal status and postmenopausal hormone
(PMH) use in NHS II but no marked differences were found among premenopausal women,
PMH never or past/current users (available upon request). Given few premenopausal women
among NHS, we cannot perform pooled-analysis of premenopausal women in NHS/NHS II.
We performed analysis by using confirmed psoriatics in NHS and NHS II. Analysis showed
that individuals with confirmed psoriasis in NHS II were associated with a significantly
increased risk of incident T2D, and multivariate-adjusted RR was 1.46 (95% CI, 1.16–1.83)
(table 5). In NHS, the RR among younger participants was 1.40 (95% CI, 0.87–2.23).
A sensitivity analysis was performed by excluding participants with baseline heart disease or
cancer and the results did not change markedly. In addition, we performed an analysis by
excluding the T2D incident cases that occurred within the first time period of follow-up and
noticed no remarkable differences either (available upon request).
Discussion
Based on three large cohort studies, our study examined the association between psoriasis
and incident T2D among all participants and those younger than 60 years during the follow-
up. We found that psoriasis was associated with an elevated risk of incident T2D among
younger individuals with psoriasis.
Past basic research and epidemiologic studies have provided evidence that psoriasis and
T2D share common risk factors. Psoriasis has been recognized as a chronic inflammatory
disease associated with expansion and activation of Th-1 and Th-17 T cells in the skin, with
upgraded production of cytokines such as tumor necrosis factor (TNF), C-reactive protein
(CRP), and interleukin (IL)-6, etc (Davidovici et al., 2010; Lowes et al., 2008). Past studies
have also suggested an inflammatory basis for diabetes and low-grade inflammation has
been shown to precede and predict the development of insulin resistance and diabetes
(Duncan et al., 2003; Garcia et al., 2010). Specifically, inflammatory cytokines such as IL-6
and TNF have been associated with insulin resistance and T2D (Hu et al., 2004; Pradhan et
al., 2001). In addition, leptin and adiponection may be involved in psoriasis and T2D,
suggesting the role of adipocytokines linking two diseases (Takahashi et al., 2008).
Moreover, environmental factors like smoking may have an impact on risk of both psoriasis
and T2D (Setty et al., 2007b; Willi et al., 2007). Therefore, immune-mediated inflammatory
process, metabolic biomarkers, and environmental factors could be the potential links
between psoriasis and diabetes.
There have been cross-sectional or case-control studies investigating the association
between psoriasis and T2D, suggesting psoriasis as a risk predictor for diabetes with the OR
ranging from 1.1 to 2.8. In view of their cross-sectional design or retrospective nature, these
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tresults may have been affected by selection and information bias. Moreover, these results
can only reflect the relationship between psoriasis and diabetes prevalence in certain
populations at best, rather than diabetes incidence. In addition, two cohort studies were
carried out while did not adjust for the main confounders (Kaye et al., 2008; Solomon et al.,
2010). Our results showed general agreement with past epidemiologic studies, and the
association seems to be modest and only among younger participants.
Psoriasis occurs in a bimodal age distribution. Type 1 psoriasis is generally early onset,
while type 2 psoriasis is late onset (Henseler and Christophers, 1985; Langley et al., 2005).
In this study, elevated risk for incident T2D was initially observed for NHS II, whereas the
multivariate-adjusted RRs for NHS and HPFS were close to null. The three cohorts have
different age distributions. For NHS II, even until the June of 2005, all were younger than 60
years. For NHS, the baseline mean age was more than 60 years. For HPFS, the baseline
mean age was more than 50 years. Given that psoriasis and T2D share some common risk
factors, individuals with type 1 psoriasis may have a higher risk of developing T2D. Based
on this rationale and the different age distribution in the three cohorts, we hypothesized that
age may be an effect modifier of the association between psoriasis and T2D.
By only including those younger than 60 years during the follow-up for NHS and HPFS,
results indicated increased risk of incident T2D associated with psoriasis, though not
significant due to small number of exposed cases. When performing pooled analysis, we
observed that psoriasis was associated with a markedly increased risk of incident T2D for
women and men younger than 60 years during the follow-up. It must be acknowledged
herein that our meta-analysis is exploratory. Because the study design across these three
cohorts is very similar, we applied a meta-analysis approach to pool the results, allowing for
the appropriate controlling for different covariates in the three cohorts. Test of heterogeneity
for these younger participants among three cohorts did not show significance.
Among younger participants, although we have limited power to analyze the impact of
psoriasis diagnosis age on risk of T2D among NHS and HPFS after excluding baseline
psoriasis, we did such analyses among NHS II participants. Our results indicated for
individuals developing psoriasis at an early age, the risk of developing T2D was much
higher while among those with psoriasis at late onset, the risk was lower. Although we
cannot define the specific proportion with type 1 psoriasis, the majority of younger
individuals with psoriasis may be type 1.
Past studies have underscored the importance of adiposity as a major determinant of diabetes
(Weinstein et al., 2004). In our models, although we have shown an independent association
between psoriasis and T2D from BMI, the RR adjusting for BMI and age is very similar to
the final multivariate-adjusted RR. Therefore, BMI is a major factor leading to the decline of
RRs after multivariate adjustment. Considering the metabolic consequences of adiposity in
the development of psoriasis (Setty et al., 2007a) and diabetes, BMI remains an important,
possibly intermediate pathway impacting the association between psoriasis and T2D.
We had confirmed the diagnosis of psoriasis for NHS and NHS II. Sensitivity analysis using
the confirmed psoriatics indicated that psoriasis was associated with a significantly elevated
risk of developing T2D. Compared with the analysis using the self-reported cases, the
magnitude of effect estimates was similar, which demonstrated the reproducibility of our
results.
It is well-accepted that there is “common soil” underlying the developing of diabetes and
cardiovascular diseases (Stern, 1995). Moreover, a close link exists between diabetes and
cancer (Giovannucci et al., 2010). A sensitivity analysis by excluding those with baseline
cancer or cardiovascular diseases did not cause material change in our results. In addition, to
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treduce reverse causality bias, all analyses were repeated by excluding T2D cases that
occurred within the first follow-up period and the results did not change markedly.
This current study has several unique strengths. The participants came from three large
cohorts of health professionals, including men and women and multiple age groups, and a
large number of T2D incidents were identified prospectively. We were able to control for
potential confounders, thereby minimizing the effect of residual confounding. Ascertainment
of the outcome, T2D, was validated. Ascertainment of the exposure, psoriasis, was assessed
as self-reports from health professionals. We also had access to a large number of confirmed
cases with psoriasis, and were able to replicate findings obtained from self-reported cases.
Moreover, to ensure the precision of the results, different sensitivity analyses were
performed. Considering the possible competing morbidities, we applied sensitivity analyses
by excluding cardiovascular disease and cancer and observed no material change of the
results.
Several limitations are worth considering. First, misclassification is possible as physician-
diagnosis of psoriasis was collected retrospectively and was not confirmed for HPFS. We
cannot obtain information for individuals with psoriasis who died before the data collection.
Potential recall bias may also be caused by retrospective data collection. However, the
healthcare-related professional background of our participants was reassuring and the
relatively higher accuracy of their report would have tended to cause non-differential
misclassification of T2D, resulting in a conservative estimate of RR. Further, we have
completed three waves of validation study for psoriasis in NHS and NHS II. A previous
study found psoriasis self-reports had more than 90% accuracy (Dominguez et al., 2009).
Actually, the results from confirmed cases further replicate the results using self-reported
cases in NHS and NHS II. Moreover, we compared the characteristics between those
responding and not-responding to the psoriasis question. The main characteristics, such as
age and BMI were similar. For NHS, NHS II and HPFS, proportion of T2D cases in
responders was 55.8, 89.3 and 53.3%, while the proportion of responders in the total
participants was 56.9, 83.5 and 51.5% respectively. Therefore, it is less likely that our
results were greatly distorted by response bias. Second, we did not have information on
severity of psoriasis and cannot evaluate the trend of risk for T2D by psoriasis severity.
Third, information on psoriasis-related therapy was unavailable. It is worth noting that
systemic steroids are not the standard of care for psoriasis in the US and adherence to long-
term use of topical steroid is generally low as steroids tend to worsen cutanous
manifestations of psoriasis (Brodell and Williams, 1999; Zaghloul and Goodfield, 2004).
Hence there is little concern about the gluconeogenic impact of systemic steroid therapy in
our study (Gomez and Frost, 1976). It was reported that TNF blocker could have a positive
influence on body weight (Saraceno et al., 2008). However, we comprehensively adjusted
for the roles of BMI. Fourth, since our current study is observational, we cannot rule out the
possibility of residual confounding by additional unmeasured or imperfectly measured
confounders. Fifth, the majority of study participants are of European ancestry, which limits
generalizing the results to other ethnicities.
In conclusion, our prospective study has provided further evidence that individuals
developing psoriasis at a younger age are at a significantly elevated risk of T2D. This
finding further underscores that psoriasis is a systemic inflammatory disorder. The
suggested association demonstrating psoriasis as a risk predictor for T2D could hold general
public health significance. Further work on the contributing mechanisms underlying this
association is warranted.
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tMETHODS
Study population
The NHS was established in 1976 when 121,700 married, female registered nurses aged 30–
55 in the US returned a baseline questionnaire about their medical history and lifestyle. NHS
II was initially established in 1989 when 116,671 female nurses aged 25–42 returned a
baseline questionnaire. The HPFS began in 1986 when 51,529 men in health professions
completed their baseline questionnaire (online supplementary table). Biennially, participants
receive a questionnaire and a response rate exceeding 90% has been achieved in each
follow-up cycle. The institutional review board of Partners Health Care System approved
this study. Participants’ completion and return of the self-administered questionnaire was
considered to imply informed consent.
Assessment of main exposure (psoriasis)
In 2008, the NHS participants were asked whether they had psoriasis diagnosed by medical
provider and the date of diagnosis (1997 or before, 1998–2001–2002–2005–2006–2007, or
2008). Of the 69,243 responders, a total of 2,161 nurses reported having been diagnosed
with psoriasis; 1,334 were prevalent cases at baseline (1997 or before), and 827 occurred
afterwards.
In 2005, NHS II participants were asked whether they had psoriasis diagnosed by medical
provider and the date of diagnosis (before 1991before 1991–1994–1995–1998–1999–2002,
or 2003–2005). Of the 97,476 responders, 2,529 women reported being diagnosed with
psoriasis; 1,378 were prevalent cases at baseline (before 1991) and 1,151 occurred
afterwards.
In 2008, HPFS participants were asked whether they had psoriasis diagnosed by medical
provider and the date of diagnosis (before 1986before 1986–1990–1991–1995–1996–2000–
2001–2004, or 2005–2008). Of the 25,635 responders, 1,171 reported being diagnosed with
psoriasis; 600 were prevalent cases at baseline (before 1986) and 571 occurred afterwards.
For NHS and NHS II, we confirmed self-reported psoriasis by using the Psoriasis Screening
Tool questionnaire (Dominguez et al., 2009). Briefly, this is a one page self-administered
questionnaire inquiring about being diagnosed with psoriasis by some type of medical
provider and psoriasis phenotypes. Based on multiple a priori hypotheses, scoring
algorithms were developed to assign a diagnosis of psoriasis depending on the response to
the questions. The screening tool can reach 99% sensitivity and 94% specificity when
screening for psoriasis (Dominguez et al., 2009). We mailed it to participants who self-
reported a diagnosis of psoriasis and the response rate reached 87% and the confirmation
rate was 92% in NHS II. .
Follow-up and assessment of outcome
The end point is diagnosis of T2D. On the baseline and biennial questionnaires, participants
responded to a question on physician-diagnosed T2D. For those reporting diabetes, a
supplementary questionnaire was then sent for confirmation of the report and ascertainment
of the date of diagnosis. The diagnosis was confirmed if at least one of the criteria of the
National Diabetes Data Group were met (He et al., 2010). The diagnostic procedure has
been verified and reached validity of 98% after medical record review by an endocrinologist
blinded to the questionnaire information (Manson et al., 1991). Moreover, a sub-study on the
prevalence of undiagnosed diabetes suggested a very low false-negative rate (Field et al.,
2001).
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In NHS, after exclusion of baseline diabetes (N=4182), unconfirmed or type 1 diabetes
(N=969), and missing date of psoriasis (N=165), 63,927 participants and 1,604 psoriasis
cases as of 2005 were included for analyses. In NHS II, after exclusion of baseline diabetes
(N=159), unconfirmed or type 1 diabetes (N=1482), and missing date of psoriasis (N=56),
95,779 participants and 2,397 psoriasis cases as of 2002 were included for analyses. In
HPFS, after exclusion of baseline diabetes (N=349), unconfirmed or type 1 diabetes
(N=570), and missing date of psoriasis (N=27), 24,689 participants and 913 psoriasis cases
as of 2004 were included. Person-years of follow-up for each participant were calculated
from the return date of baseline questionnaire (1996 for NHS, 1991 for NHS II and 1986 for
HPFS) to the date of diagnosis of T2D, or the end of follow-up (June 2008 for NHS, June
2007 for NHS II and Jan 2006 for HPFS), whichever came first. We conducted Cox
proportional hazards analysis stratified by age and 2-year follow-up interval to estimate the
age-adjusted and multivariate RR and 95% CI for the association between psoriasis and
incident T2D.
The time-varying covariates adjusted in the multivariate analysis were updated during
follow-up, including age, body mass index, smoking status, physical activity, alcohol intake,
race, family history of diabetes, hypertension, hypercholesterolemia, current aspirin use,
multi-vitamin use, menopausal status and PMH use (for women only).
Further analyses were performed for NHS and HPFS by including only those younger than
60 years during the follow-up (For NHS II, all met this criteria). Then pooled-analysis was
conducted using a meta-analytic approach to evaluate the pooled RR for T2D by psoriasis
among participants younger than 60 during the follow-up from the three cohorts. We tested
the between-studies heterogeneity and estimated the overall association from random effects
(weighted proportionately to the inverse of the sum of the study specific variance plus the
common between-studies variance) or fixed effects models (weighted proportionately to the
inverse of the study-specific variance) (Smith-Warner et al., 2006).
For analysis of psoriasis diagnosis age and T2D in NHS II, we excluded psoriasis before
baseline because we have no information on their diagnosis date. Age at diagnosis were
categorized into three groups (<40, 40–49 and ≥ 50 years).
We also performed a sensitivity analysis by excluding participants who had a history of
cardiovascular disease or cancer at baseline or had reported any of these conditions on a
previous questionnaire. In addition, another sensitivity analysis was carried out by excluding
diabetes occurring within the first 2-year time period of follow-up.
All statistical analyses were conducted using Statistical Analysis System software (SAS,
version 9.1; SAS Institute Inc, Cary, NC). All statistical tests were 2-tailed, and the
significance level was set at P <0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 3
Relative risks of incident type 2 diabetes according to psoriasis among younger (<60 years during the follow-
up) US women and men 1
Study Diabetes cases Person-years Age-adjusted RR (95% CI) Multivariate RR 2 (95% CI)
NHS
No psoriasis 733 165,508 1.00 1.00
Psoriasis 23 2,982 1.73 (1.14–2.62) 1.35 (0.89–2.05)
HPFS
No psoriasis 622 245,644 1.00 1.00
Psoriasis 23 6,610 1.30 (0.86–1.97) 1.20 (0.79–1.82)
NHS/NHSII
No psoriasis 4,568 1,636,217 1.00 1.00
Psoriasis 156 29,141 1.76 (1.50–2.06) 1.26 (1.08–1.48)
NHS/NHSII/HPFS
No psoriasis 5,190 1,881,861 1.00 1.00
Psoriasis 179 35,751 1.69 (1.46–1.96) 1.26 (1.08–1.46)
Abbreviations: CI, confidence interval; RR, relative risk.
1
NHS II data not shown because study participants were all <60y during the follow-up, the same as table 2.
2
Simultaneously adjusted for age, body mass index (<21.0, 21.0–22.9, 23.0–24.9, 25.0–26.9, 27.0–29.9, 30.0–32.9, 33.0–34.9, 35.0–39.9 or ≥40.0
kg/m2), smoking (never, past, current with 1–14, 15–24 or ≥25 cigarettes/day), alcohol intake (no, <4.9, 5.0–14.9 or ≥15.0 g/d), physical activity
(<3.0, 3.0–8.9, 9.0–17.9, 18.0–26.9 or ≥27.0 metabolic equivalent hours/wk), race (Caucasian, Asian, Hispanic or African American), family
history of diabetes (yes or no), hypertension (yes or no), hypercholesterolemia (yes or no), current aspirin use (yes or no), multi-vitamin use (yes or
no), postmenopausal hormone use (for women only, premenopause, never, current or past users).
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Table 4
Association of psoriasis diagnosis age with incidence of type 2 diabetes (NHS II)
Psoriasis diagnosis age Diabetes cases Person-years Age-adjusted RR (95% CI) Multivariate RR 1 (95% CI)
No psoriasis 3,835 1,470,709 1.00 1.00
Diagnosis age <40 y 18 2,503 3.09 (1.94–4.92) 1.81 (1.14–2.89)
Diagnosis age 40–49 y 24 2,318 2.41 (1.61–3.60) 1.31 (0.88–1.96)
Diagnosis age >=50 y 2 589 0.60 (0.15–2.40) 0.48 (0.12–1.94)
Abbreviations: CI, confidence interval; RR, relative risk.
1
Simultaneously adjusted for age, body mass index (<21.0, 21.0–22.9, 23.0–24.9, 25.0–26.9, 27.0–29.9, 30.0–32.9, 33.0–34.9, 35.0–39.9 or ≥40.0
kg/m2), smoking (never, past, current with 1–14, 15–24 or ≥25 cigarettes/day), alcohol intake (no, <4.9, 5.0–14.9 or ≥15.0 g/d), physical activity
(<3.0, 3.0–8.9, 9.0–17.9, 18.0–26.9 or ≥27.0 metabolic equivalent hours/wk), race (Caucasian, Asian, Hispanic or African American), family
history of diabetes (yes or no), hypertension (yes or no), hypercholesterolemia (yes or no), current aspirin use (yes or no), multi-vitamin use (yes or
no), postmenopausal hormone use (premenopause, never, current or past users).
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Table 5
Association of psoriasis with incidence of type 2 diabetes in confirmed cases of psoriasis (NHS II)
Sensitivity analysis Diabetes cases Person-years Age-adjusted RR (95% CI) Multivariate RR 1 (95% CI)
NHS For all participants
No psoriasis 4,198 725,208 1.00 1.00
Psoriasis 82 10,456 1.33 (1.07–1.66) 1.14 (0.92–1.42)
For participants younger than 60 y
No psoriasis 738 166,169 1.00 1.00
Psoriasis 18 2,321 1.73 (1.08–2.76) 1.40 (0.87–2.23)
NHS II
No psoriasis 3,891 1,483,100 1.00 1.00
psoriasis 77 13,768 1.92 (1.53–2.40) 1.46 (1.16–1.83)
Abbreviations: CI, confidence interval; RR, relative risk.
1
Simultaneously adjusted for age, body mass index (<21.0, 21.0–22.9, 23.0–24.9, 25.0–26.9, 27.0–29.9, 30.0–32.9, 33.0–34.9, 35.0–39.9 or ≥40.0
kg/m2), smoking (never, past, current with 1–14, 15–24 or ≥25 cigarettes/day), alcohol intake (no, <4.9, 5.0–14.9 or ≥15.0 g/d), physical activity
(<3.0, 3.0–8.9, 9.0–17.9, 18.0–26.9 or ≥27.0 metabolic equivalent hours/wk), race (Caucasian, Asian, Hispanic or African American), family
history of diabetes (yes or no), hypertension (yes or no), hypercholesterolemia (yes or no), current aspirin use (yes or no), multi-vitamin use (yes or
no), postmenopausal hormone use (premenopause, never, current or past users).
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